Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: 26(9), P. 3684 - 3695

Published: June 14, 2024

Abstract Aim To analyse the association between serum bile acid (BA) profile and heart failure (HF) with preserved ejection fraction (HFpEF) in patients metabolic dysfunction‐associated fatty liver disease (MAFLD). Methods We enrolled 163 individuals biopsy‐proven MAFLD undergoing transthoracic echocardiography for any indication. HFpEF was defined as left ventricular >50% at least one echocardiographic feature of HF (left diastolic dysfunction, abnormal atrial size) sign or symptom. Serum levels 38 BAs were analysed using ultra‐performance liquid chromatography coupled tandem mass spectrometry. Results Among (mean age 47.0 ± 12.8 years, 39.3% female), 52 (31.9%) 43 (26.4%) met pre‐HFpEF criteria, detected. ursodeoxycholic (UDCA) hyocholic (HCA) species lower achieved statistical significance after correction multiple comparisons. Furthermore, decreases glycoursodeoxycholic tauroursodeoxycholic associated status. Conclusions In this exploratory study, specific UDCA HCA status adults biopsy‐confirmed MAFLD.

Language: Английский

---

Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion of patients with or at risk metabolic dysfunction-associated steatotic liver disease (MASLD) who had PEth levels indicative harmful consumption, and assess associations between major adverse outcomes (MALOs). conducted cohort study involving persons tested in Stockholm, Sweden 2012 2020 (N=46,406), including various (SLD) subtypes individuals without SLD. Cumulative incidences MALOs were calculated different groups while accounting competing risk. Cox regression was evaluate association baseline incidence MALOs. Among 6,377 presumed MASLD, 1,294 (20%) 0.05 0.30 μmol/L (35-210 ng/ml), indicating excessive intake (MetALD), 854 (13%) values >0.30 μmol/L, alcohol-related (ALD). Patients MASLD 0.05-0.30 similar median FIB-4 scores cirrhosis prevalence those <0.05 μmol/L. However, higher cumulative compared Elevated significantly linked rates cirrhosis, even after adjustments age, sex, SLD subtype, score. ALD highest worst prognosis. valuable distinguishing subtypes, especially ALD, predicts people There controversy regarding proposed most definition suggesting that elevated consumption should be classified having MetALD. Here, we address this challenge by classifying utilizing phosphatidylethanol (PEth), direct reliable Our analysis large cohort-comprising 46,406 patients-revealed using objective may tool MetALD, strongly associated known Integrating testing into routine diagnostic evaluations could enhance knowledge on underlying pathophysiology SLD, reduce potential misclassification, ultimately improve patient enabling clinicians offer appropriate therapies. Further research needed validate these findings other populations explore integration broader clinical guidelines managing

Language: Английский

---

Generation and characterization of a chronic in vitro model to study the early stage of metabolic dysfunction-associated steatotic liver disease (MASLD)

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2025, Volume and Issue: unknown, P. 167886 - 167886

Published: May 1, 2025

Language: Английский

---

Impact of ectopic fat on brain structure and cognitive function: A systematic review and meta-analysis from observational studies

Frontiers in Neuroendocrinology, Journal Year: 2023, Volume and Issue: 70, P. 101082 - 101082

Published: July 1, 2023

Language: Английский

---

One‐hour post‐load glucose levels are associated with hepatic steatosis assessed by transient elastography

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 26(2), P. 682 - 689

Published: Nov. 12, 2023

Abstract Aim To examine the association between 1‐hour plasma glucose (PG) concentration and markers of non‐alcoholic fatty liver disease (NAFLD) assessed by transient elastography (TE). Methods We performed TE in 107 metabolically well‐characterized non‐diabetic White individuals. Controlled attenuation parameter (CAP) was used to quantify steatosis, while stiffness marker (LS) evaluate fibrosis. Results correlated significantly with PG ( r = 0.301, P < 0.01), fasting insulin 0.285, 2‐hour 0.257, 0.02), homeostasis model assessment index resistance 0.252, high‐density lipoprotein cholesterol −0.252, body mass (BMI; 0.248, 0.02) age 0.212, 0.03), after correction for age, sex BMI. In a multivariable linear regression analysis, β 0.274, 0.008) levels 0.225, 0.029) were found be independent predictors CAP. After excluding subjects prediabetes, sole predictor CAP variation 0.442, 0.001). logistic model, we observed that group ≥ 8.6 mmol/L (155 mg/dL) had higher risk steatosis (odds ratio 3.98, 95% confidence interval 1.43‐11.13; than individuals mmol/L, potential confounders. No LS. Conclusion Our data confirm is associated signs NAFLD, even among normal tolerance, categorized as low canonical diagnostic standards. safe low‐impact approach could employed stratifying profile these patients, high level accuracy.

Language: Английский

---

Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission

Journal of Health Population and Nutrition, Journal Year: 2024, Volume and Issue: 43(1)

Published: Aug. 31, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic disease.

Language: Английский

---

Hepatic MR imaging using IDEAL-IQ sequence: Will Gd-EOB-DTPA interfere with reproductivity of fat fraction quantification?

World Journal of Clinical Cases, Journal Year: 2023, Volume and Issue: 11(25), P. 5887 - 5896

Published: Aug. 31, 2023

Iterative decomposition of water and fat with echo asymmetry least squares estimation quantification sequence (IDEAL-IQ) is based on chemical shift-based separation technique to get proton density fraction. Multiple studies have shown that using IDEAL-IQ test the stability repeatability liver acceptable has high accuracy.To explore whether Gadoxetate Disodium (Gd-EOB-DTPA) interferes measurement hepatic content quantified evaluate robustness this technique.IDEAL-IQ was used quantify at 3.0T in 65 patients injected Gd-EOB-DTPA contrast. After injection, estimated four times, fraction (FF) R2* were measured following time points: Pre-contrast, between portal phase (70 s) late (180 s), delayed (5 min) hepatobiliary (20 min). One-way repeated-measures analysis conducted difference FFs points. Bland-Altman plots adopted assess FF changes before after injection contrast agent. P < 0.05 considered statistically significant.The assessment points liver, spleen spine showed no significant differences, measurements yielded good consistency T1 T2 [95% confidence interval: -0.6768%, 0.6658%], T3 (-0.3900%, 0.3178%), T4 (-0.3750%, 0.2825%). increased significantly (P 0.0001).Using measure FF, we can obtain results will not be affected by Gd-EOB-DTPA. The reproducibility makes it available scanning interval save during multiphase examinations.

Language: Английский

---

A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol

Journal of Comparative Effectiveness Research, Journal Year: 2024, Volume and Issue: 13(10)

Published: Sept. 20, 2024

Aim: A clinical decision support (CDS) tool for metabolic dysfunction-associated steatohepatitis (MASH) was developed to align health systems with guidelines detailed in the MASH Clinical Care Pathway and improve patients' proactive self-management of their disease. The includes a provider-facing web-based application mobile (app) patients. This protocol outlines pilot study that will systematically evaluate implementation real-world practice settings. Materials & methods: research use simultaneous mixed-methods design is guided by Consolidated Framework Implementation Research. CDS be piloted ≥3 months at multiple US-based sites eligible gastroenterologists hepatologists (n = 5–10 per site) patients 50–100 or suspected MASH. Each site may choose one all focus areas within (i.e., risk stratification, screening referral, patient care management), based on on-site capabilities. Prior end period, providers complete quantitative surveys partake semi-structured interviews. Outcomes include understanding feasibility implementing settings, its effectiveness increasing screenings stratification MASH, ability provider knowledge barriers adoption tool's capacity enhance engagement satisfaction care. Conclusion: Findings inform scalable ensure are identified early, referred specialty when necessary managed appropriately. Successful integration app can contribute better outcomes facilitating active participation management condition.

Language: Английский

---

FLI and FIB-4 in diagnosing Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care: High Prevalence and Risk of Significant Disease.

Annals of Hepatology, Journal Year: 2024, Volume and Issue: unknown, P. 101584 - 101584

Published: Oct. 1, 2024

Public health policies in metabolic dysfunction-associated steatotic liver disease (MASLD) are still lacking. This study aims to estimate the prevalence and severity of MASLD primary care (PHC) through non-invasive markers.

Language: Английский

---

Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction

Cardiovascular & Haematological Disorders - Drug Targets, Journal Year: 2024, Volume and Issue: 24(4), P. 211 - 217

Published: Nov. 20, 2024

Nonalcoholic steatohepatitis (NASH) is a type of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocyte injury and inflammation, in addition to only the presence steatosis NAFLD. We review existing data on available novel therapies for NASH NAFLD also discuss several development. assessed searching databases PubMed, EMBASE, Web Science (SCI) from their inception dates until September 15, 2024. Search terms used were: disease, steatohepatitis, inflammation injury.Until very recently, therapeutic lifestyle change was primary modality treatment NASH, including modification diet physical activity. The FDA recently approved resmetirom using its expedited approval mechanism NASH. There are pharmacotherapies development which aim at weight loss, insulin sensitization improvement lipid levels, although some drugs may have multiple effects discussed. availability offers patients with an effective adjunctive therapy changes. Several other currently being tested will add our armamentarium.

Language: Английский

---